首页> 外文期刊>ACS applied materials & interfaces >Endogenous Stimuli-Responsive Nucleus-Targeted Nanocarrier for Intracellular mRNA Imaging and Drug Delivery
【24h】

Endogenous Stimuli-Responsive Nucleus-Targeted Nanocarrier for Intracellular mRNA Imaging and Drug Delivery

机译:用于细胞内mRNA成像和药物递送的内源性刺激核靶向纳米载体

获取原文
获取原文并翻译 | 示例
           

摘要

Drug resistance arising from overexpressed efflux transporters increases the efflux of drugs and accordingly restricts the efficacy of chemotherapy. Advances in nanocarriers have provided potential strategies to cope with drug resistance. Herein, endogenous stimuli-responsive nucleus-targeted nanocarrier is developed for intracellular multidrug resistance protein 1 (MRP1) mRNA imaging and drug delivery. This nanocarrier (AuNP-mRS-DSs) is composed of three parts: (i) gold nanoparticle (AuNP), for loading DNA and quenching fluorescence; (ii) mRNA recognition sequence (mRS) modified on the surface of gold nanoparticle by gold-thiol bond, for the specific recognition of MRP1 mRNA; (iii) detachable subunit (DS), hybridized with Cy5-labeled DNA linker and nucleolin recognition motif and grafted onto mRS via the DNA linker for loading doxorubicin (Dox), binding to nucleolin, and reporting signal. First, nucleolin recognition motif of this nanocarrier targets nucleolin, which is overexpressed on cancer cells surface; subsequently, the whole nanocarrier enters the cell via nucleolin-mediated internalization. Subsequently, mRS will specifically recognize overexpressed MRP1 mRNA, leading to the release of trapped DS and followed by AuNP-quenched Cy5 fluorescence recovery. Finally, by translocation of nucleolin from cytoplasm to nucleus, the DS targets nucleus to delivery Dox. By intracellular fluorescence imaging, the differentiation of drug-resistant and nondrug-resistant cells could be achieved. Compared with free Dox (IC50 8.00 mu M), Dox-loaded AuNP-mRS-DSs (IC50 = 2.20 mu M) performed superior suppression efficacy toward drug-resistant cancer cells. Such a nanocarrier provides an effective strategy to synergistically sense and circumvent drug resistance, which may be exploited as a candidate for personalized medicine.
机译:过表达的流出转运仪引起的耐药性增加了药物的流出,因此限制了化疗的功效。纳米载波的进步提供了应对耐药性的潜在策略。在此,开发内源性刺激核靶纳米骨载体用于细胞内多药抗性蛋白1(MRP1)mRNA成像和药物递送。该纳米载波(AUNP-MRS-DSS)由三个部分组成:(i)金纳米粒子(AUNP),用于加载DNA和淬火荧光; (ii)通过金 - 硫醇键在金纳米粒子的表面上改性的mRNA识别序列(MRS),用于MRP1 mRNA的具体识别; (iii)可拆卸的亚基(DS),用Cy5标记的DNA接头和核仁识别基序杂交,并通过DNA接头接枝到MRS上,用于装载多柔比蛋白(DOX),结合核仁和报告信号。首先,该纳米载体的核仁识别基序靶向核仁,其在癌细胞表面上过表达;随后,整个纳米载波通过核仁介导的内化进入细胞。随后,MRS专门识别过表达的MRP1 mRNA,导致被困DS的释放,然后是AUNP淬火CY5荧光回收。最后,通过将核仁从细胞质转移到细胞核,DS靶向输送DOX。通过细胞内荧光成像,可以实现耐药性和非固体抗性细胞的分化。与自由DOX(IC50& 8.00 mu m)相比,DOX负载的AUNP-MRS-DSS(IC50 = 2.20 mu m)对耐药性癌细胞进行了卓越的抑制效果。这种纳米载波提供了有效的策略,以协同意识和避难的耐药性,这可以被利用为个性化药物的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号